Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia

Supplemental Figure 1 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia

<p>Supplemental Figure 1: Overall and progression-free survival for patients, according to whether the transplant followed first line or second line treatment.</p>

Spremljeno u:

Bibliografski detalji
Glavni autor:	Amir T. Fathi (15313195) (author)
Daljnji autori:	Haesook T. Kim (15313198) (author), Robert J. Soiffer (15313201) (author), Mark J. Levis (15313204) (author), Shuli Li (15313207) (author), Annette S. Kim (15117505) (author), Zachariah DeFilipp (15313210) (author), Areej El-Jawahri (15313213) (author), Steve L. McAfee (15313216) (author), Andrew M. Brunner (15313219) (author), Philip C. Amrein (15313222) (author), Alice S. Mims (11016414) (author), Laura W. Knight (15313225) (author), Devon Kelley (15313228) (author), AJ S. Bottoms (15313231) (author), Lindsey H. Perry (15313234) (author), Jonathan L. Wahl (15313237) (author), Jennifer Brock (15313240) (author), Elayne Breton (15313243) (author), Dylan M. Marchione (14935655) (author), Vincent T. Ho (15313246) (author), Yi-Bin Chen (15313249) (author)
Izdano:	2025
Teme:	Cancer Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase I clinical trials Drug Targets Oncoprotein & tumor suppressor drug targets Hematological Cancers Leukemias Immunotherapy Stem cell transplantation
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!

Slični predmeti

Supplemental Figure 2 from Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for <i>IDH1</i>-Mutated Acute Myeloid Leukemia
od: Amir T. Fathi (15313195)
Izdano: (2025)

Supplementary Dataset S1 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
od: Srivandana Akshintala (16610490)
Izdano: (2025)

Supplementary Table S5 from Phase I trial of Ganitumab plus Dasatinib to Cotarget the Insulin-Like Growth Factor 1 Receptor and Src Family Kinase YES in Rhabdomyosarcoma
od: Srivandana Akshintala (16610490)
Izdano: (2025)

Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
od: Evan C. Chen (15054014)
Izdano: (2025)

Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
od: Evan C. Chen (15054014)
Izdano: (2025)

Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
od: Evan C. Chen (15054014)
Izdano: (2025)

Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
od: Evan C. Chen (15054014)
Izdano: (2025)

Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
od: Evan C. Chen (15054014)
Izdano: (2025)

Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
od: Evan C. Chen (15054014)
Izdano: (2025)

Supplemental Figure S1 from Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy
od: Zev A. Wainberg (15047031)
Izdano: (2025)

Supplementary Figure S1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
od: Fabrice Barlesi (15045504)
Izdano: (2025)

Supplementary Figure S2 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
od: Fabrice Barlesi (15045504)
Izdano: (2025)

Supplementary Figure S3 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
od: Fabrice Barlesi (15045504)
Izdano: (2025)

Supplementary Figure S4 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
od: Fabrice Barlesi (15045504)
Izdano: (2025)

Supplementary Figure S5 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
od: Fabrice Barlesi (15045504)
Izdano: (2025)

Supplementary Figure S1 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
od: Chong Kin Liam (15331321)
Izdano: (2025)

Supplementary Figure S2 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
od: Chong Kin Liam (15331321)
Izdano: (2025)

Supplementary Figure S3 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
od: Chong Kin Liam (15331321)
Izdano: (2025)

Supplementary Figure S4 from Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in <i>EGFR</i>-Mutant NSCLC with EGFR Inhibitor Resistance Due to <i>MET</i> Amplification: INSIGHT Final Analysis
od: Chong Kin Liam (15331321)
Izdano: (2025)

Supplementary Tables S1-14 from Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple <i>PIK3CA</i> Mutations
od: Smruthy Sivakumar (15053536)
Izdano: (2025)

Supplementary Figure 1 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
od: John R. Davies (17314989)
Izdano: (2025)

Supplementary Figure 2 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
od: John R. Davies (17314989)
Izdano: (2025)

Supplementary Figure 3 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
od: John R. Davies (17314989)
Izdano: (2025)

Supplementary Table 2 from Polymorphisms in <i>Cyclooxygenase</i>, <i>Lipoxygenase</i>, and <i>TP53</i> Genes Predict Colorectal Polyp Risk Reduction by Aspirin in the seAFOod Polyp Prevention Trial
od: John R. Davies (17314989)
Izdano: (2025)

Supplementary Figure S1 from Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101)
od: Roberto Carmagnani Pestana (15294422)
Izdano: (2025)

Supplementary Figure S1 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
od: Sied Kebir (15048732)
Izdano: (2025)

Supplementary Figure S2 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
od: Sied Kebir (15048732)
Izdano: (2025)

Supplementary Figure S3 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
od: Sied Kebir (15048732)
Izdano: (2025)

Supplementary Figure S4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
od: Sied Kebir (15048732)
Izdano: (2025)

Supplementary Tables S1-4 from A Sequential Targeting Strategy Interrupts AKT-Driven Subclone-Mediated Progression in Glioblastoma
od: Sied Kebir (15048732)
Izdano: (2025)

Supplementary Table S1 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
od: Erwin Tomasich (15052256)
Izdano: (2025)

Supplementary Table S2 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
od: Erwin Tomasich (15052256)
Izdano: (2025)

Supplementary Table S3 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
od: Erwin Tomasich (15052256)
Izdano: (2025)

Supplementary Table S4 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
od: Erwin Tomasich (15052256)
Izdano: (2025)

Supplementary Table S5 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
od: Erwin Tomasich (15052256)
Izdano: (2025)

Supplementary Table S6 from Frequent Overexpression of HER3 in Brain Metastases from Breast and Lung Cancer
od: Erwin Tomasich (15052256)
Izdano: (2025)

Figure S1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
od: Niklas Klümper (15048887)
Izdano: (2025)

Supplementary Data TS1 from Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
od: Niklas Klümper (15048887)
Izdano: (2025)

Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder
od: Roger Li (17078665)
Izdano: (2025)

Supplementary Figure S1 from Devimistat in Combination with Gemcitabine and Cisplatin in Biliary Tract Cancer: Preclinical Evaluation and Phase Ib Multicenter Clinical Trial (BilT-04)
od: Arathi Mohan (15561346)
Izdano: (2025)

Cannot write session to /tmp/vufind_sessions/sess_b627i32eveqc36nf4cscsk66h3